748 Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1797637896968077312 |
|---|---|
| author | Daniel Olson Manish Sharma Erminia Massarelli Jonathan Thompson Rachel E Sanborn Ralph J Hauke Anthony W Tolcher Elizabeth Davis Conor Steuer Muhammad Furqan John Hamm Doug Laux David Berz Wade T Iams Vasily Andrianov Brianne O’Neill Yaiza Diaz De Durana |
| author_facet | Daniel Olson Manish Sharma Erminia Massarelli Jonathan Thompson Rachel E Sanborn Ralph J Hauke Anthony W Tolcher Elizabeth Davis Conor Steuer Muhammad Furqan John Hamm Doug Laux David Berz Wade T Iams Vasily Andrianov Brianne O’Neill Yaiza Diaz De Durana |
| author_sort | Daniel Olson |
| collection | DOAJ |
| first_indexed | 2024-03-11T12:55:55Z |
| format | Article |
| id | doaj.art-cbd533f340f04e57bd954ddd0c27ef8f |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-03-11T12:55:55Z |
| publishDate | 2023-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-cbd533f340f04e57bd954ddd0c27ef8f2023-11-03T17:10:07ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262023-11-0111Suppl 110.1136/jitc-2023-SITC2023.0748748 Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumorsDaniel Olson0Manish Sharma1Erminia Massarelli2Jonathan Thompson3Rachel E Sanborn4Ralph J Hauke5Anthony W Tolcher6Elizabeth Davis7Conor Steuer8Muhammad Furqan9John Hamm10Doug Laux11David Berz12Wade T Iams13Vasily Andrianov14Brianne O’Neill15Yaiza Diaz De Durana164University of Chicago Comprehensive Cancer Center, Chicago, IL, USA3START Midwest, Grand Rapids, MI, USA7City of Hope, Duarte, CA, USA10Medical College of Wisconsin, Milwaukee, WI, USA1Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA6Nebraska Cancer Specialists, Omaha, NE, USA13NEXT Oncology, San Antonio, TX, USA9Vanderbilt University Medical Center, Nashville, TN, USA8Winship Cancer Institute of Emory University, Atlanta, GA, USA2University of Iowa, Carver College of Medicine, Iowa City, IA, USA11Norton Healthcare, Louisville, KY, USA2University of Iowa, Carver College of Medicine, Iowa City, IA, USA5Valkyrie Clinical Trials, Los Angeles, CA, USA9Vanderbilt University Medical Center, Nashville, TN, USA12Inhibrx, Inc, La Jolla, CA, USA12Inhibrx, Inc, La Jolla, CA, USA12Inhibrx, Inc, La Jolla, CA, USA |
| spellingShingle | Daniel Olson Manish Sharma Erminia Massarelli Jonathan Thompson Rachel E Sanborn Ralph J Hauke Anthony W Tolcher Elizabeth Davis Conor Steuer Muhammad Furqan John Hamm Doug Laux David Berz Wade T Iams Vasily Andrianov Brianne O’Neill Yaiza Diaz De Durana 748 Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors Journal for ImmunoTherapy of Cancer |
| title | 748 Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors |
| title_full | 748 Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors |
| title_fullStr | 748 Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors |
| title_full_unstemmed | 748 Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors |
| title_short | 748 Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors |
| title_sort | 748 phase 1 2 study of the hexavalent ox40 agonist inbrx 106 alone and in combination with pembrolizumab in select solid tumors |
| work_keys_str_mv | AT danielolson 748phase12studyofthehexavalentox40agonistinbrx106aloneandincombinationwithpembrolizumabinselectsolidtumors AT manishsharma 748phase12studyofthehexavalentox40agonistinbrx106aloneandincombinationwithpembrolizumabinselectsolidtumors AT erminiamassarelli 748phase12studyofthehexavalentox40agonistinbrx106aloneandincombinationwithpembrolizumabinselectsolidtumors AT jonathanthompson 748phase12studyofthehexavalentox40agonistinbrx106aloneandincombinationwithpembrolizumabinselectsolidtumors AT rachelesanborn 748phase12studyofthehexavalentox40agonistinbrx106aloneandincombinationwithpembrolizumabinselectsolidtumors AT ralphjhauke 748phase12studyofthehexavalentox40agonistinbrx106aloneandincombinationwithpembrolizumabinselectsolidtumors AT anthonywtolcher 748phase12studyofthehexavalentox40agonistinbrx106aloneandincombinationwithpembrolizumabinselectsolidtumors AT elizabethdavis 748phase12studyofthehexavalentox40agonistinbrx106aloneandincombinationwithpembrolizumabinselectsolidtumors AT conorsteuer 748phase12studyofthehexavalentox40agonistinbrx106aloneandincombinationwithpembrolizumabinselectsolidtumors AT muhammadfurqan 748phase12studyofthehexavalentox40agonistinbrx106aloneandincombinationwithpembrolizumabinselectsolidtumors AT johnhamm 748phase12studyofthehexavalentox40agonistinbrx106aloneandincombinationwithpembrolizumabinselectsolidtumors AT douglaux 748phase12studyofthehexavalentox40agonistinbrx106aloneandincombinationwithpembrolizumabinselectsolidtumors AT davidberz 748phase12studyofthehexavalentox40agonistinbrx106aloneandincombinationwithpembrolizumabinselectsolidtumors AT wadetiams 748phase12studyofthehexavalentox40agonistinbrx106aloneandincombinationwithpembrolizumabinselectsolidtumors AT vasilyandrianov 748phase12studyofthehexavalentox40agonistinbrx106aloneandincombinationwithpembrolizumabinselectsolidtumors AT brianneoneill 748phase12studyofthehexavalentox40agonistinbrx106aloneandincombinationwithpembrolizumabinselectsolidtumors AT yaizadiazdedurana 748phase12studyofthehexavalentox40agonistinbrx106aloneandincombinationwithpembrolizumabinselectsolidtumors |